Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | PON1 | P27169 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25187590 | 0.86 | PARP1 (0.33) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL30235082 | 0.86 | PARP1 (0.33) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL31302852 | 0.80 | PARP1 (0.35) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL25607482 | 0.75 | PARP1 (0.37) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL25187586 | 0.75 | PARP1 (0.34) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL8478795 | 0.75 | HPGD (0.44) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL30618929 | 0.73 | P2RX7 (0.30) | — | |
| SCHEMBL30618930 | 0.73 | CYP1A2 (0.30) | CYP1A2CYP2D6ALPGCYP2C19SMN1; SMN2 | |
| SCHEMBL30018760 | 0.72 | PARP1 (0.49) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL25093447 | 0.72 | PARP1 (0.49) | PARP1CYP1A2CYP2D6ALPGCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885CYP1A2 2630/4885CYP2D6 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.